N-phenylformamide is a white, crystalline solid that is commonly used as a reagent in organic synthesis. It can be synthesized by the reaction of aniline with formic acid. N-phenylformamide is a useful starting material for the preparation of other organic compounds, such as pharmaceuticals and pesticides. It has also been studied for its potential applications in materials science and nanotechnology.'
formanilide : A member of the class of formamides that is formamide in which one of the amino hydrogens is replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7671 |
| CHEMBL ID | 1232659 |
| CHEBI ID | 42416 |
| SCHEMBL ID | 2463 |
| SCHEMBL ID | 17211133 |
| MeSH ID | M0133420 |
| Synonym |
|---|
| BIDD:GT0244 |
| CHEMBL1232659 |
| chebi:42416 , |
| inchi=1/c7h7no/c9-6-8-7-4-2-1-3-5-7/h1-6h,(h,8,9 |
| formanilide |
| formamide, n-phenyl- |
| nsc8862 |
| phenyl formamide |
| formylaniline |
| aniline, n-formyl- |
| wln: vhmr |
| n-formylaniline |
| formamidobenzene |
| carbanilaldehyde |
| nsc-8862 |
| 103-70-8 |
| n-phenylformamide |
| NCGC00091354-01 |
| AR-360/40233696 |
| phenylformamide |
| brn 0906934 |
| einecs 203-136-0 |
| hsdb 5355 |
| ai3-01089 |
| ccris 4650 |
| nsc 8862 |
| GHL.PD_MITSCHER_LEG0.1270 |
| formanilide, 99% |
| AKOS000297095 |
| FAN , |
| MLS002415732 , |
| smr001370900 |
| F0047 |
| A800788 |
| NCGC00091354-02 |
| n-phenyl-formamide |
| unii-2805xea9cl |
| 2805xea9cl , |
| 4-12-00-00368 (beilstein handbook reference) |
| dtxcid205338 |
| NCGC00257825-01 |
| dtxsid3025338 , |
| cas-103-70-8 |
| tox21_200271 |
| FT-0626529 |
| n-phenylformamide [hsdb] |
| formanilide [mi] |
| SCHEMBL2463 |
| n-phenylmethanamide |
| bdbm74419 |
| cid_7671 |
| n-formyl-aniline |
| forrnanilide |
| anilineformaldehyde |
| W-109055 |
| n-formanilide |
| SCHEMBL17211133 |
| mfcd00003276 |
| formanilid |
| n-phenylformimidic acid |
| Q2689660 |
| SY011224 |
| D70279 |
| AS-56859 |
| CS-W017768 |
| EN300-19846 |
| Class | Description |
|---|---|
| formamides | Amides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H). |
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Smad3 | Homo sapiens (human) | Potency | 1.5849 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 44.6684 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 55.0927 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 55.5533 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 69.3576 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 0.0282 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 47.3079 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| geminin | Homo sapiens (human) | Potency | 0.1487 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1134000 | Inhibition of chymotrypsin (unknown origin) | 1977 | Journal of medicinal chemistry, Apr, Volume: 20, Issue:4 | Quantitative structure-activity relationships of chymotrypsin. On the predictive value of correlation equations. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.36) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||